- By insider
CEO of Biomarin Pharmaceutical Inc (BMRN) Jean Jacques Bienaime sold 120,000 shares of BMRN on 10/28/2016 at an average price of $81.3 a share. The total sale was $9.8 million.
Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse. Biomarin Pharmaceutical Inc has a market cap of $13.16 billion; its shares were traded at around $80.52 with and P/S ratio of 13.36.
-
Warning! GuruFocus has detected 3 Warning Signs with BMRN. Click here to check it out.
-
The intrinsic value of BMRN
CEO Recent Trades:
-
CEO Jean Jacques Bienaime sold 120,000 shares of BMRN stock on 10/28/2016 at the average price of $81.3. The price of the stock has decreased by 0.96% since.
-
CEO Jean Jacques Bienaime sold 41,666 shares of BMRN stock on 10/17/2016 at the average price of $84.39. The price of the stock has decreased by 4.59% since.
-
CEO Jean Jacques Bienaime sold 64,125 shares of BMRN stock on 10/14/2016 at the average price of $86.96. The price of the stock has decreased by 7.41% since.
For the complete insider trading history of BMRN, click here
.This article first appeared on GuruFocus.
-
Warning! GuruFocus has detected 3 Warning Signs with BMRN. Click here to check it out.
-
The intrinsic value of BMRN